A Phase II clinical trial of CPI-613 in patients with relapsed or refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 (United States). The gene discussed is BCL2; the disease is Burkitt lymphoma.